Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.62 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.58 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.53 |
| ▸ | NLN | Q9BYT8 | 5/20 | 0.50 |
| ▸ | MASP2 | O00187 | 1/20 | 0.49 |
| ▸ | F11 | P03951 | 1/20 | 0.48 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18241797 | 0.84 | SSTR1 (0.47) | SSTR1SCN10AF11KLKB1 | |
| Hydrochloric Acid SCHEMBL17008908 | 0.83 | SSTR1 (0.47) | SSTR1SCN10AF11KLKB1 | |
| Hydrochloric Acid SCHEMBL17008937 | 0.83 | SSTR1 (0.47) | SSTR1SCN10AF11KLKB1 | |
| SCHEMBL17022187 | 0.80 | F11 (0.51) | SSTR1SCN10AF11KLKB1 | |
| SCHEMBL1196577 | 0.79 | CYP1A2 (0.43) | SSTR1PDE10ASCN10ANLN | |
| Hydrochloric Acid SCHEMBL29758961 | 0.79 | F11 (0.50) | SSTR1SCN10AF11KLKB1 | |
| Hydrochloric Acid SCHEMBL29758967 | 0.79 | F11 (0.50) | SSTR1SCN10AF11KLKB1 | |
| SCHEMBL4324766 | 0.77 | SSTR1 (1.00) | SSTR1 | |
| SCHEMBL20900140 | 0.77 | MASP2 (0.55) | SSTR1PDE10AMASP2NPY5RSCN2A | |
| SCHEMBL18480825 | 0.77 | MASP2 (0.55) | SSTR1PDE10AMASP2NPY5RSCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753578-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | Novartis AG (CH) | 2020-12-23 | — | — | EP | disclosed |
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| EP-3082877-B1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2019-08-28 | — | — | EP | disclosed |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-08-27 | — | — | US | disclosed |
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2019-06-27 | — | — | US | disclosed |
| US-20180244717-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-08-30 | — | — | US | disclosed |
| US-9988420-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| EP-3310813-A1 | ANTIBODY DRUG CONJUGATES | Novartis AG (CH) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016203432-A1 | ANTIBODY DRUG CONJUGATES | NOVARTIS AG (CH) | 2016-12-22 | — | — | WO | disclosed |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2016-10-27 | — | — | US | disclosed |
| EP-3082877-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | Novartis AG (CH) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015095301-A2 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | IRM LLC (BM) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787480-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | SSTR1 1111/4885PDE10A 4361/4885SCN10A 4094/4885 |
| US-20190194315-A1 | ANTIBODY DRUG CONJUGATES | EPCAM, CDH1, VIM | SSTR1 4833/4885PDE10A 3965/4885SCN10A 3270/4885 |
| US-10392421-B2 | Cytotoxic peptides and conjugates thereof | CD47, NGLY1, VIP | SSTR1 1111/4885PDE10A 4361/4885SCN10A 4094/4885 |
| US-20180244717-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | SSTR1 1111/4885PDE10A 4361/4885SCN10A 4094/4885 |
| US-20160311853-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, NGLY1, VIP | SSTR1 1111/4885PDE10A 4361/4885SCN10A 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.